ArticleCNS drugs2015

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.

Barbara H Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.